Navigation Links
AMITIZA 8 mcg now available to treat irritable bowel syndrome
Date:5/27/2008

Bethesda, Md., and Deerfield, Ill., May 27, 2008 Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA (lubiprostone) 8 mcg capsules are now available by prescription in pharmacies across the U.S. for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years and older. AMITIZA 24 mcg capsules have been available by prescription to treat Chronic Idiopathic Constipation in adults since 2006.

AMITIZA is the only widely available FDA-approved prescription treatment option that can provide overall symptom relief for the millions of adult women in the U.S. with IBS-C.

AMITIZA has a mechanism of action that works locally in the intestine to increase fluid secretion, resulting in increased passage of stool and alleviating symptoms associated with Chronic Idiopathic Constipation.

Although it is not well understood how AMITIZA works to reduce symptoms in patients with IBS-C, ex vivo animal studies suggest that AMITIZA stimulates recovery of mucosal barrier function by restoring tight junction protein complexes.

The effects of IBS-C can be debilitating and far-reachingaffecting many aspects of a persons life, said Charles Baum, M.D., gastroenterologist, executive medical director, Gastroenterology and Internal Medicine, at Takeda Pharmaceuticals North America, Inc. The availability of AMITIZA makes it possible for appropriate patients to receive a widely available prescription medication that can be an important tool to help treat this condition.

I am very pleased with the quick commercial launch of AMITIZA 8 mcg for this particular indication as it could provide a treatment option to many adult women suffering from IBS-C, said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals.

AMITIZA was developed by Sucampo Pharmaceuticals and is co-marketed in the U.S. by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America, Inc.

About Irritable Bowel Syndrome with Constipation (IBS-C)

IBS is a disorder characterized by symptoms including abdominal discomfort or pain, bloating and changes of bowel habits such as constipation and/or diarrhea. There are three main types of IBS: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed constipation and diarrhea (IBS-M). In IBS-C, symptoms are present for at least 12 weeks (not necessarily consecutive) over a 12-month period. Although people with IBS-C report many of the symptoms associated with constipation, the presence of abdominal discomfort or pain is what differentiates IBS-C from chronic constipation. IBS is approximately two to two-and-a-half times more prevalent in women than men.

About AMITIZA (lubiprostone) for Chronic Idiopathic Constipation and IBS-C

Indication

AMITIZA (lubiprostone) is indicated for the treatment of Chronic Idiopathic Constipation (24 mcg) in adults and for Irritable Bowel Syndrome with Constipation (8 mcg) in women > 18 years old.

Important Safety Information

AMITIZA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating physician to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.

The safety of AMITIZA in pregnancy has not been evaluated in humans. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.

Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their physician.

AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe.

Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their physician.

In clinical trials of AMITIZA (24 mcg) in patients with Chronic Idiopathic Constipation, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).

In clinical trials of AMITIZA (8 mcg) in patients with Irritable Bowel Syndrome with Constipation, the most common adverse reactions (incidence > 4%) were nausea (8%), diarrhea (7%), and abdominal pain (5%).


'/>"/>

Contact: Dave Buckalew
dbuckalew@tpna.com
224-554-5486
Ketchum
Source:Eurekalert

Related medicine news :

1. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
2. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
3. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
4. Tickets Still Available for Detroit Uncorked;
5. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
6. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
7. Fingertip Formulary Mobile(TM) is Now Available for Physicians and Other Healthcare Providers Free on PDAs
8. New Resource for Taking Care of Aging Parents Available in Beta
9. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
10. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
11. Updated Brochure on Gynecologic Cancer Treatments Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an innovative ... has completed a round of funding to accelerate its growth strategies. The $3.5 ... Capital is a growth equity firm focused on investments in healthcare and technology ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
Breaking Medicine Technology: